Back

Notification report

Full notification file


General information

Notification Number
B/NL/03/05

Member State to which the notification was sent
Netherlands

Date of acknowledgement from the Member State Competent Authority
29/08/2003

Title of the Project
A double-blind, randomized, placebo controlled dose-escalating phase 1 study to evaluate the safety and immunogenicity of a MVA HIV-1 vaccine administered by three different routes and at three different dosage levels in HIV-uninfected healthy volunteers at lower risk of infection.

Proposed period of release:
01/02/2004 to 28/02/2005

Name of the Institute(s) or Company(ies)
International AIDS Vaccine Initiative, New York, USA, New York, USA;


3. Is the same GMO release planned elsewhere in the Community?
Yes:
United Kingdom;

Has the same GMPt been notified elsewhere by the same notifier?
Yes

If yes, notification number(s):


GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
Modified vaccinia virus Ankara-based anti-HIV vaccine (MVA.HIVA)

Information relating to the recipient or parental organisms from wich the GMO is derived

Common Name	Genus	Species	Subspecies	Strain	Pathovar
Cowpox vaccinia virus	Orthopoxvirus	vaccinia virus		Ankara

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known